This increase was due to products portfolio expansion, as well as to the proven efficiency of the Ozone model of business and steady investment planning. Ozone launched several new products in 2008: Trachisept and Aqua Maris, for the OTC segment, and Alozur, Zitrocin and Indapamid Ozone for the Rx segment, and extended several of its lines such as Cara, Extremvit and Entran.

The company extended its partnerships in both production and distribution and continued the forecast organizational development by investing approximately 20% of its turnover in logistics, trade actions, marketing activities and medical detailing.

Ozone also decided to enter the mass market segment (hypermarkets, supermarkets, gas stations networks) with a selected portfolio, in order to maintain close connection with its consumers.

“The 2008 figures are a proof of the viability of Ozone business pattern and of its effective implementation. Our results validate the financial and structural objectives set for 2008 in the context of the particular challenges on the market. We have been rigorously following the plan of organizational restructuring established for 2008 and the results underline our strategy which is making Ozone an increasingly important player in both the Rx and OTC markets”, said Christopher Henwood, CEO of Ozone Laboratories Group.

Ozone Laboratories is active on the Romanian market since 2002 and is present in 6 countries in Central and Eastern Europe.

Ozone has several partnerships ongoing with important manufacturers in Europe, Asia and the US and offers integrated health solutions.

In Romania, its products are highly positioned on the pain killers, vitamins and antibiotics market.